Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.

The efficacy of proton pump inhibitors (PPIs) for treating functional dyspepsia (FD) is not well established.
This study, named the SAMURAI study, aimed to assess the efficacy and dose-response relationship of rabeprazole in Japanese patients with FD in a multicentre, double-blinded, randomised, placebo-controlled trial.
Investigated FD was diagnosed using the Rome III criteria. Subjects who did not respond to 1 week of single-blind placebo treatment in a run-in period were randomly assigned to 8 weeks of double-blind treatment with rabeprazole 10 mg, 20 mg, 40 mg or placebo, once daily. Dyspeptic symptoms were assessed by a dyspepsia symptom questionnaire (7-point Likert scale) and symptom diary.
Of 392 subjects entered into the run-in period, 338 were randomly assigned. Although there was no significant difference between placebo and rabeprazole groups in complete symptom relief for four major dyspeptic symptoms, the satisfactory symptom relief of rabeprazole 20 mg was significantly higher than placebo according to the dyspepsia symptom questionnaire (45.3% vs. 28.2%, P = 0.027) and the symptom diary assessment (48.7% vs. 30.0%, P = 0.016). The efficacy was not influenced by syndrome type or Helicobacter pylori status. No statistically significant differences in the incidence of adverse events were seen among treatment groups.
Rabeprazole 20 mg once daily but not 10 or 40 mg significantly provides satisfactory symptom relief for functional dyspepsia (ClinicalTrials.gov, Number NCT01089543).
AuthorsR Iwakiri, K Tominaga, K Furuta, M Inamori, T Furuta, H Masuyama, K Kanke, A Nagahara, K Haruma, Y Kinoshita, K Higuchi, S Takahashi, M Kusano, K Iwakiri, M Kato, M Hongo, H Hiraishi, S Watanabe, H Miwa, Y Naito, K Fujimoto, T Arakawa
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 38 Issue 7 Pg. 729-40 (Oct 2013) ISSN: 1365-2036 [Electronic] England
PMID23957383 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2013 John Wiley & Sons Ltd.
Chemical References
  • Proton Pump Inhibitors
  • Rabeprazole
  • Double-Blind Method
  • Dyspepsia (drug therapy)
  • Female
  • Follow-Up Studies
  • Helicobacter Infections (drug therapy)
  • Helicobacter pylori (isolation & purification)
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Proton Pump Inhibitors (adverse effects, therapeutic use)
  • Rabeprazole (adverse effects, therapeutic use)
  • Surveys and Questionnaires
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: